Adverse effects of golimumab in the treatment of rheumatologic diseases

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.13, Iss.1, 2014-01, pp. : 103-112

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 9, Iss. 3, 2009-09 ,pp. : 295-314

Bentham Science Publishers

Access to resources Recommend Favorite

Finding a Place for Interleukin-1 Inhibitors in the Treatment of Rheumatologic Diseases

Current Pharmaceutical Design, Vol. 21, Iss. 17, 2015-05 ,pp. : 2198-2205

Bentham Science Publishers

Access to resources Recommend Favorite

Using Biologic Agents in Pediatric Rheumatologic Diseases

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 9, Iss. 1, 2010-01 ,pp. : 41-45

Bentham Science Publishers

Access to resources Recommend Favorite

Efficacy and Adverse Effects of Medications Used in the Treatment of Glaucoma

By Camras C.B. Toris C.B. Tamesis R.R.

Drugs & Aging, Vol. 15, Iss. 5, 1999-11 ,pp. : 377-388

Adis International

Access to resources Recommend Favorite

Golimumab for the Treatment of Psoriatic Arthritis: A NICE Single Technology Appraisal

By Yang Huiqin

PharmacoEconomics, Vol. 30, Iss. 4, 2012-04 ,pp. : 257-270

Adis International

Access to resources Recommend Favorite